Actuate Therapeutics (ACTU) Cash & Equivalents (2023 - 2025)

Actuate Therapeutics (ACTU) has reported Cash & Equivalents for 3 consecutive years, with $13.2 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Cash & Equivalents rose 52.28% year-over-year to $13.2 million; the TTM figure through Dec 2025 stood at $13.2 million (up 52.28% YoY), while the FY2025 annual figure was $13.2 million, up 52.28% from the prior year.
• Cash & Equivalents eased to $13.2 million in Q4 2025 per ACTU's latest filing, from $16.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $16.9 million in Q3 2025 and bottomed at $351709.0 in Q2 2024.
• Historically, Cash & Equivalents has averaged $8.2 million across 3 years, with a median of $7.6 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 1746.03% in 2025 and fell as far as 25.15% in 2025.
• Actuate Therapeutics' Cash & Equivalents stood at $3.0 million in 2023, then soared by 192.08% to $8.6 million in 2024, then surged by 52.28% to $13.2 million in 2025.
• Business Quant data shows ACTU's Cash & Equivalents at $13.2 million in Q4 2025, $16.9 million in Q3 2025, and $6.5 million in Q2 2025.